Telomir Pharmaceuticals

Update in progress

TELO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Telomir Pharmaceuticals, Inc. is a preclinical biotechnology company developing small-molecule therapeutics aimed at upstream drivers of aging and age-related diseases. Its lead candidate, Telomir-1, is an oral metal ion regulator intended to protect against conditions such as Wilson’s disease, type 2 diabetes, AMD, oncology, epigenetic disorders, Alzheimer’s disease, and Progeria. Formerly Metallo Therapies, it renamed to Telomir in 2022. Incorporated in 2021 and based in Miami, Florida.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive